U.S. FDA warns on Daiichi Sankyo blood pressure drugs

July 3 Wed Jul 3, 2013 10:40am EDT

July 3 (Reuters) - U.S. health regulators warned on Wednesday that Daiichi Sankyo Inc's blood pressure drugs Benicar, Benicar HCT, Azor and Tribenzor can cause severe, chronic diarrhea and substantial weight loss, sometimes requiring hospitalization.

The Food and Drug Administration said the intestinal problems, known as sprue-like enteropathy, can develop months to years after starting on the drug, which is known generically as olmesartan medoxomil.

The drug is one of a class of drugs known as angiotensin II receptor blockers, or ARBs. The agency said sprue-like enteropathy has not been detected with other ARB drugs.

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
if the F.D.A. would have tests done on these drugs before releasing them, then they could avoid all this harm to people. the F.D.A. are letting the drug companies release anything on people and then destroying people. when side effects happen, then the F.D.A. wants to add a warning. what a crick of bull they are. they destroyed my body with a poison called statins and flouroquinolones. do not trust doctors or F.D.A. THEY ARE NOTHING MORE THAN KILLERS WHO ARE NOT PROSECUTED.

Jul 03, 2013 11:17am EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.